Hypertension

Curing, preventing and reversing diabetes with a commonly available antiasthmatic drug Montelukast: Montelukast-based therapy for TIIDM and obesity-associated metabolic deficits: Montelukast (trade name: Singulair and others), a vasodilator used in the treatment of asthma, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 9/March/2020, 11.08 pm
Curing, preventing and reversing diabetes with a commonly available antiasthmatic drug Montelukast: Montelukast-based therapy for TIIDM and obesity-associated metabolic deficits: Montelukast (trade name: Singulair and others), a vasodilator used in the treatment of asthma, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 9/March/2020, 11.08 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Curing, preventing and reversing diabetes with a commonly available blood pressure drug Hydralazine: Hydralazine-based therapy for TIIDM and obesity-associated metabolic deficits: Hydralazine (trade name: Apresoline, BiDil, and others), a vasodilator used in the treatment of high blood pressure,  cardiac failure and others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 14/November/2019, 9.58 am
Curing, preventing and reversing diabetes with a commonly available blood pressure drug Hydralazine: Hydralazine-based therapy for TIIDM and obesity-associated metabolic deficits: Hydralazine (trade name: Apresoline, BiDil, and others), a vasodilator used in the treatment of high blood pressure,  cardiac failure and others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 14/November/2019, 9.58 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Cardiovascular Polypill-LAAH attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction:   A four-component Polypill-LAAH consisting of Losartan(25 mg), Amlodipine (2.5 mg), Atorvastatin (10 mg), and Hydrochlorothiazide (12·5 mg)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 1/October/2019, 12.04 pm
Cardiovascular Polypill-LAAH attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction:   A four-component Polypill-LAAH consisting of Losartan(25 mg), Amlodipine (2.5 mg), Atorvastatin (10 mg), and Hydrochlorothiazide (12·5 mg)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 1/October/2019, 12.04 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Molecular therapy for Pulmonary arterial hypertension: Lactolose (brand name: Cholac, Generlac, Consulose, Duphalac, others) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 6/March/2019, 9.41 pm
Molecular therapy for Pulmonary arterial hypertension: Lactolose (brand name: Cholac, Generlac, Consulose, Duphalac, others) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 6/March/2019, 9.41 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:   A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine“[the number 1 journal in General…

read more

Repurposing the anti-hyperglycemic drug Pioglitazone into an anti-pulmonary arterial hypertension drug: Pioglitazone (brand name: Actos) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 12/January/2019, 8.23 am
Repurposing the anti-hyperglycemic drug Pioglitazone into an anti-pulmonary arterial hypertension drug: Pioglitazone (brand name: Actos) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 12/January/2019, 8.23 am 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine“[the number 1 journal in General…

read more

Probiotic-based therapy for pulmonary arterial hypertension (PAH): Bifidobacterium lactis LKM512-containing yogurt inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 17/November/2018, 12.11 am
Probiotic-based therapy for pulmonary arterial hypertension (PAH): Bifidobacterium lactis LKM512-containing yogurt inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 17/November/2018, 12.11 am 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General…

read more
Start Typing